open access

Vol 3, No 1 (2010)
Published online: 2010-03-19
Get Citation

Raport z 7th Inhibitor Workshop for Opinion Leaders in Haemophilia, Antalya, Turcja, 24-26 czerwca 2009 roku

Redakcja JTM
Journal of Transfusion Medicine 2010;3(1):35-46.

open access

Vol 3, No 1 (2010)
Published online: 2010-03-19


Not available


Not available
Get Citation
About this article

Raport z 7th Inhibitor Workshop for Opinion Leaders in Haemophilia, Antalya, Turcja, 24-26 czerwca 2009 roku


Journal of Transfusion Medicine


Vol 3, No 1 (2010)



Published online


Bibliographic record

Journal of Transfusion Medicine 2010;3(1):35-46.


Redakcja JTM

References (51)
  1. Shattil SJ, Bennett JS. Platelets and their membranes in hemostasis: physiology and pathophysiology. Ann Intern Med. 1981; 94(1): 108–118.
  2. Krudysz-Amblo J, Parhami-Seren B, Butenas S, et al. Quantitation of anti-factor VIII antibodies in human plasma. Blood. 2009; 113(11): 2587–2594.
  3. Brackmann HH, Effenberger E, Hess L, et al. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis. 2000; 11 Suppl 1: S39–S44.
  4. Rodriguez-Merchan EC. Haemophilic synovitis: basic concepts. Haemophilia. 2007; 13 Suppl 3: 1–3.
  5. Gomperts ED, Astermark J, Gringeri A, et al. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors. Blood Rev. 2008; 22 Suppl 1: S1–11.
  6. Brackmann HH, Effenberger W, Hess L, et al. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)? Eur J Haematol Suppl. 1998; 63: 18–23.
  7. Rodriguez-Merchan EC, Quintana M, Jimenez-Yuste V, et al. Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients). Haemophilia. 2007; 13(5): 613–619.
  8. Hillarp A, Berntorp E. Non-inhibitory antibodies in the MIBS cohort. J Thromb Haemostas. 2009; 7(supl. 2): abstract.
  9. Windyga J, Chojnowski K, Klukowska A, et al. Zasady postępowania w hemofilii A i B. Acta Haematol Pol. 2008; 39: 537–564.
  10. Brackmann HH, Lenk H, Scharrer I, et al. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia. 1999; 5(3): 203–206.
  11. Santagostino E, Morfini M, Auerswald GKH, et al. Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needs. Haemophilia. 2009; 15(5): 983–989.
  12. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost. 2008; 34(7): 683–691.
  13. Ahnström J, Berntorp E, Lindvall K, et al. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004; 10(6): 689–697.
  14. Tjønnfjord GE, Tjønnfjord GE, Brinch L, et al. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia. 2004; 10(2): 174–178.
  15. Bakewell SJ, Nestor P, Prasad S, et al. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A. 2003; 100(24): 14205–14210.
  16. Daldrup-Link HE, Steinbach L. MR imaging of pediatric arthritis. Magn Reson Imaging Clin N Am. 2009; 17(3): 451–467.
  17. DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia. 2007; 13 Suppl 1: 1–22.
  18. Brill A, Elinav H, Varon D. Differential role of platelet granular mediators in angiogenesis. Cardiovasc Res. 2004; 63(2): 226–235.
  19. Doria AS, Lundin B, Kilcoyne RF, et al. Reliability of progressive and additive MRI scoring systems for evaluation of haemophilic arthropathy in children: expert MRI Working Group of the International Prophylaxis Study Group. Haemophilia. 2005; 11(3): 245–253.
  20. DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol. 2007; 138(3): 305–315.
  21. Lauroua P. Ferrer A.M., Guerin V. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors. Haemophilia. 2009; 29: 1–8.
  22. Kraut EH, Aledort LM, Arkin S, et al. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. Haemophilia. 2007; 13(5): 508–517.
  23. Di Paola J, Aledort L, Britton H, et al. Application of current knowledge to the management of bleeding events during immune tolerance induction. Haemophilia. 2006; 12(6): 591–597.
  24. Calvete JJ. Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost. 1994; 72(1): 1–15.
  25. Gringeri AA. 10-year, randomized clinical trial on prophylaxis vs. on demand treatment in children with haemophilia A: the E. S P R I T study. Haemophilia. 2008; 14(supl. 2): 99.
  26. White JG, Krumwiede MD, Cocking-Johnson D, et al. Induction of GPIb/IX-vWF Receptor-Ligand Translocation on Surface-Activated Platelets. Arteriosclerosis, Thrombosis, and Vascular Biology. 1995; 15(5): 642–654.
  27. Jiménez-Yuste V, Rodriguez-Merchan E, Alvarez M, et al. Controversies and Challenges in Elective Orthopedic Surgery in Patients With Hemophilia and Inhibitors. Seminars in Hematology. 2008; 45: S64–S67.
  28. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6): 535–544.
  29. Zwall RFA. Membrane and lipid involvement In blond coagulation. 1978; 515: 163–205.
  30. Hay CRM. The epidemiology of factor VIII inhibitors. Haemophilia. 2006; 12 Suppl 6: 23–28.
  31. Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia. 2003; 9(3): 261–268.
  32. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost. 2008; 34(7): 683–692.
  33. Coppola A, Franchini M, Tagliaferri A, et al. Prophylaxis in people with haemophilia. Thromb Haemost. 2009; 101: 674–681.
  34. Habermann B, Hochmuth K, Hovy L, et al. Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis. 1996; 26 Suppl 1(6): 118–123.
  35. Hermans C. Clinical relevance of subclinical bleeds. Abstract book 7 th inhibitor workshoop for opinion leaders in haemophilia. , Antalya Turkey 2009: 11.
  36. Kreuz W, Escuriola-Ettinghausen C, Mentzer D, et al. Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high-responding inhibitors. Blood. 2000; 96(11): 266a.
  37. Kruse-Jarres R, Barnett B, Leissinger C. Immune tolerance induction for the eradication of inhibitors in patients with hemophilia A. Expert Opin Biol Ther. 2008; 8(12): 1885–1896.
  38. Leissinger CA, Becton DL, Ewing NP, et al. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007; 13(3): 249–255.
  39. Lusher J, Ingerslev J, Roberts H, et al. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis. 1998; 9(2): 119–128.
  40. Manno CS. Treatment options for bleeding episodes in patients undergoing immune tolerance therapy. Haemophilia. 1999; 5 Suppl 3: 33–41.
  41. Odeyemi IAO, Danø AM. Optimising immune tolerance induction strategies in the management of haemophilia patients with inhibitors: a cost-minimisation analysis. Curr Med Res Opin. 2009; 25(1): 239–250.
  42. Oldenburg J, Schwaab R, Brackmann HH. Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol’: Predictive Parameter for Therapy Duration and Outcome. Vox Sanguinis. 1999; 77(Suppl. 1): 49–54.
  43. Petrini P, Klementz G. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy. Blood Coagul Fibrinolysis. 1998; 9 Suppl 1: S143–S146.
  44. Saxon BR, Shanks D, Jory CB, et al. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost. 2001; 86(4): 1126–1127.
  45. Schapiro AD, Gilchrist GS, Hoots WK, et al. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemostas. 1998; 80: 773–778.
  46. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia. 2004; 10(4): 347–351.
  47. Tjønnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia. 2004; 10 Suppl 2: 41–45.
  48. Valentino L.A. FEIBA prophylaxis in hemophilia A patients with inhibitors results in a 95% reduction in bleeding episodes. Bangkok, Thailand: Poster presented at 26 th World Federation of Haematology Congress October Bangkok, 2004.
  49. VALENTINO LA. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia. 2006; 12(s5): 26–31.
  50. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia. 2003; 9(4): 436–463.
  51. Windyga J, Chojnowski K, Klukowska A, et al. Zasady postępowania w hemofilii A i B powikłanej inhibitorem. Acta Haematologica Polonica. 2008; 38(3): 565–579.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Journal of Transfusion Medicine dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: